UK advises against covering Novartis' Kymriah for adults; Ex-Mast chief Brian Culley appointed CEO at BioTime
→ Right on the heels of endorsing the use of Novartis’ CAR-T Kymriah in children, the UK drug price watchdog NICE is turning its thumbs down for extending its welcome to adults. “However, NICE does recognise that Novartis’ tisagenlecleucel-T, also known as Kymriah, has significant clinical benefits, and would welcome further discussions on its cost-effectiveness.”
→ Degenerative disease specialist BioTime $BTX has tapped Brian Culley as its new CEO, taking up a role previously shared by Adi Mohanty and Michael West. Culley helmed Mast Therapeutics for seven years before a failed lead program dragged it down and left it with little option other than serving as a shell for Savara’s reverse merger. West will now move onto the chief executive role at AgeX, a BioTime affiliate focused on age-related degenerative ailments.
→ Pharming’s application to expand the label for its hereditary angioedema drug has been spurned by regulators. The FDA is asking for an additional trial before it can consider Ruconest as a prophylactic treatment.
→ Roche is rolling out new apps designed to help support the way medical teams treat cancer patients.